Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Head & Neck 2Genitourinary 2Gastrointestinal 2Breast 2Sarcoma 1Other solid neoplasm 1Gynecologic 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 28Melanoma 9Triple Negative Breast Neoplasms 8Lung Neoplasms 6Carcinoma, Renal Cell 6Squamous Cell Carcinoma of Head and Neck 5Colorectal Neoplasms 5Small Cell Lung Carcinoma 4Pancreatic Neoplasms 4Breast Neoplasms 4Uterine Cervical Neoplasms 3Stomach Neoplasms 3Sarcoma 3Ovarian Neoplasms 3Neoplasms 3Mesothelioma 3Lymphoma 3Head and Neck Neoplasms 3Adenocarcinoma of Lung 3Adenocarcinoma Of Esophagus 3Adenocarcinoma 3Parkinson Disease 4, Autosomal Dominant Lewy Body 2Neoplasm Metastasis 2Nasopharyngeal Carcinoma 2NSCLC 2Liver Neoplasms 2Kidney Neoplasms 2Esophageal Squamous Cell Carcinoma 2Endometrial Neoplasms 2Colonic Neoplasms 2

Interventions

pembrolizumab 38Nivolumab 24atezolizumab 10Ipilimumab 7Carboplatin 6avelumab 5Paclitaxel 5Magnetic Resonance Spectroscopy 5Docetaxel 5Cyclophosphamide 5fludarabine 4cabozantinib 4Specimen Handling 4Pemetrexed 4regorafenib 3Interleukin-2 3Gemcitabine 3130-nm albumin-bound paclitaxel 3spartalizumab 2lenvatinib 2epacadostat 2durvalumab 2aldesleukin 2Taxes 2Immune Checkpoint Inhibitors 2Cisplatin 2Biopsy 2Albumin-Bound Paclitaxel 2zanidatamab 1veliparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Transitional Cell × spartalizumab × Thoracic × Clear all
NCT04802876 2025-03-21

ACROPOLI

SOLTI Breast Cancer Research Group

Phase 2 Active not recruiting
184 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmSarcomaThoracic

Adenocarcinoma Of Esophagus, Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Uveal Melanoma, Anus Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Neoplasms, Unknown Primary, Sarcoma, Thyroid Neoplasms, Cholangiocarcinoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04060342 2022-08-18

GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma

Gossamer Bio Inc.

Phase 1 Terminated
61 enrolled
BreastGastrointestinalGenitourinaryHead & NeckThoracic

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Stomach Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡